INNOCAN PHARMA Business Summary

Innocan Pharma Corp (INNPF) operates a dual-track revenue model centered on pharmaceutical technology and consumer wellness. The company generates the majority of its current revenue through its 60%-owned subsidiary, BI Sky Global Ltd, which utilizes a high-volume e-commerce strategy to sell CBD-integrated and non-CBD topical wellness products across platforms like Amazon. Simultaneously, its pharmaceutical segment focuses on the development and future licensing of proprietary drug delivery platforms, most notably the LPT-CBD liposome-loaded injectable technology designed for controlled-release, non-opioid pain management in both human and veterinary markets. As of early 2026, Innocan reported trailing twelve-month revenues of approximately $27 million, primarily driven by its wellness division. The company competes directly with Lexaria Bioscience, IGC Pharma, and Tilray, distinguishing itself through its specialized focus on long-acting injectable cannabinoid delivery systems rather than traditional oral or combustible formats. The leadership team is anchored by Co-Founder and CEO Iris Bincovich, a veteran of global health sector management and business development, and Co-Founder and CTO Nir Avram, who previously served as VP of R&D at Perrigo and Emilia Cosmetics. The founding group also includes serial biotech entrepreneur Yoram Drucker, known for co-founding NASDAQ-listed firms Pluri (formerly Pluristem) and Brainstorm Cell Therapeutics. Innocan’s scientific credibility is bolstered by its Scientific Advisory Board, which features Professor Yechezkel Barenholz, the primary inventor of the FDA-approved liposomal cancer drug Doxil. While the company recently withdrew its NYSE American registration in February 2026 to maintain its current listing structure, it continues to leverage its high-pedigree technical team to advance 505(b)(2) FDA pathways for its pharmaceutical assets.